A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA

Completed · Phase 2 · Has a placebo group

Conditions studied: Influenza

In brief

The purpose of this study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy adults

Key facts

Study ID

NCT00958126

Run by

Seqirus

People needed

1313

Starts

2009-08-01

Expected to finish

2010-04-01

Last updated by the study team

2017-11-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or female aged 18 and older, inclusive, at the time of providing informed consent.
• Females of child bearing potential (i.e., ovulating, pre-menopausal, not surgically sterile) must be abstinent or be willing to use a medically accepted contraceptive regimen for the duration of the study. Females of child bearing potential must return a negative urine pregnancy test result at enrolment and prior to each study vaccination.

You may not qualify if…

• Known hypersensitivity to a previous dose of influenza virus vaccine or allergy to eggs, chicken protein, thimerosal, neomycin, polymyxin, or any components of the Study Vaccine.

Where it is running

• Study Site — Huntsville, Alabama, United States
• Study Site — San Diego, California, United States
• Study Site — Melbourne, Florida, United States
• Study Site — Peoria, Illinois, United States
• Study Site — South Bend, Indiana, United States
• Study Site — Metairie, Louisiana, United States
• Study Site — Baltimore, Maryland, United States
• Study Site — Rockville, Maryland, United States
• Study Site — Austin, Texas, United States
• Study Site — Fort Worth, Texas, United States
• Study Site — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.